Stockscreener 앱 받기
6.40
2.44%
-0.16
시간 외 거래:
6.45
0.05
+0.78%
전일 마감가:
$6.56
열려 있는:
$6.52
하루 거래량:
1.75M
Relative Volume:
1.51
시가총액:
$261.08M
수익:
-
순이익/손실:
$-54.19M
주가수익비율:
-2.4806
EPS:
-2.58
순현금흐름:
$-37.34M
1주 성능:
+19.63%
1개월 성능:
+41.59%
6개월 성능:
+3.06%
1년 성능:
+39.13%
1일 변동 폭
$6.2849
$6.6892
1주일 범위
$4.87
$7.3236
52주 변동 폭
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
명칭
Abeona Therapeutics Inc
전화
646-813-4701
주소
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
ABEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.40 | 261.08M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Oppenheimer | Outperform |
| 2024-07-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-30 | 개시 | Stifel | Buy |
| 2020-11-11 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-02-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-10 | 재개 | Cantor Fitzgerald | Neutral |
| 2019-08-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2019-08-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-06-27 | 개시 | Mizuho | Buy |
| 2018-10-12 | 개시 | Mizuho | Buy |
| 2018-06-05 | 개시 | Seaport Global Securities | Buy |
| 2017-11-08 | 개시 | SunTrust | Buy |
| 2017-10-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-10-10 | 개시 | Citigroup | Buy |
| 2017-10-05 | 재확인 | Maxim Group | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-18 | 재확인 | Maxim Group | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-01-06 | 개시 | Jefferies | Buy |
| 2016-09-29 | 재확인 | Maxim Group | Buy |
모두보기
Abeona Therapeutics Inc 주식(ABEO)의 최신 뉴스
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy - Genetic Engineering and Biotechnology News
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
Abeona Therapeutics (ABEO) Gains FDA Approval for Gene Therapy | - GuruFocus
Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - MSN
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11 - Smartkarma
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid FDA Appr - GuruFocus
Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease - Contract Pharma
FDA approves Abeona’s Zevaskyn - The Pharma Letter
Abeona prices rare cell disorder gene therapy at $3.1m - pharmaphorum
Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. - Olean Times Herald
Stifel lifts Abeona stock target to $21, maintains buy rating By Investing.com - Investing.com Canada
Stifel lifts Abeona stock target to $21, maintains buy rating - Investing.com
FDA Approves Abeona Gene Therapy for Healing Wounds From Rare, Inherited Skin Disease - MedCity News
Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy - insights.citeline.com
Abeona cell therapy approved by FDA for rare skin condition - BioPharma Dive
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid Zevaskyn - GuruFocus
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease By Stocktwits - Investing.com India
Cleveland company receives FDA approval for rare disease treatment - Crain's Cleveland Business
FDA Approval of Zevaskyn Boosts ABEO Prospects | ABEO Stock News - GuruFocus
Abeona’s rare skin disease gene therapy approved by FDA - BioWorld MedTech
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Says US FDA Approves Zevaskyn to Treat Wounds in Patients With Genetic Skin Disease - marketscreener.com
US FDA approves first cell-based gene therapy for rare genetic skin disorder - Reuters
Abeona Therapeutics Hosts Conference Call and Webcast - TipRanks
FDA Greenlights Abeona Therapeutics' Gene Therapy Zevaskyn for R - GuruFocus
Abeona Therapeutics (ABEO) Jumps on FDA Nod for Gene Therapy Zev - GuruFocus
FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel - CGTLive®
Abeona stock gains on FDA nod for gene therapy (ABEO:NASDAQ) - Seeking Alpha
US FDA approves Abeona's skin disorder therapy - marketscreener.com
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the - GlobeNewswire
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewswire Inc.
Is Abeona Therapeutics Inc (NASDAQ: ABEO) Stock Poised for More Growth? - Marketing Sentinel
How did Abeona Therapeutics Inc (ABEO) fare last session? - uspostnews.com
Global Fanconi Anemia Market Insights: Jasper Therapeutics, - openPR.com
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.84, Down -0.21 - DWinneX
Abeona Therapeutics Inc (ABEO) looking to reclaim success with recent performance - Sete News
ABEO Shares Experience Surge in Value - knoxdaily.com
Stock Performance Spotlight: Abeona Therapeutics Inc (ABEO) Ends the Day at 5.22, Down by -1.14 - DWinneX
Examining ABEO’s book value per share for the latest quarter - uspostnews.com
Why Invest In Abeona Therapeutics Inc (ABEO) Stock? - Marketing Sentinel
(ABEO) Investment Analysis and Advice - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients - Seeking Alpha
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.85, Down -1.42 - DWinneX
Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025 - CGTLive®
Wellington Management Group LLP Acquires Shares of 93,289 Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside - Seeking Alpha
Abeona Therapeutics Inc (ABEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):